Back to top
more

Supernus Pharmaceuticals (SUPN)

(Delayed Data from NSDQ)

$33.00 USD

33.00
395,924

+1.11 (3.48%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $32.97 -0.03 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Company Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

General Information

Supernus Pharmaceuticals, Inc

9715 Key West Avenue

ROCKVILLE, MD 20850

Phone: 301-838-2500

Fax: 301-838-2501

Web: http://www.supernus.com

Email: peter.vozzo@westwicke.com

Industry Medical - Generic Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

11/13/2024

EPS Information

Current Quarter EPS Consensus Estimate 0.39
Current Year EPS Consensus Estimate 2.00
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

11/13/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 31.89
52 Week High 35.44
52 Week Low 21.99
Beta 0.88
20 Day Moving Average 358,461.94
Target Price Consensus 39.25

SUPN

% Price Change
4 Week 6.80
12 Week 13.40
YTD 14.03
% Price Change Relative to S&P 500
4 Week 2.77
12 Week 8.13
YTD -9.07
Share Information
Shares Outstanding (millions) 55.10
Market Capitalization (millions) 1,818.46
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 16.50
Trailing 12 Months 366.67
PEG Ratio NA
EPS Growth
vs. Previous Year 1,900.00%
vs. Previous Quarter NA
   
Sales Growth
vs. Previous Year 24.17%
vs. Previous Quarter 17.18%
   
Price Ratios
Price/Book 1.90
Price/Cash Flow 20.82
Price / Sales 2.89
ROE
9/30/24 Pending Next EPS Report
6/30/24 0.56
3/31/24 -1.68
ROA
9/30/24 Pending Next EPS Report
6/30/24 0.40
3/31/24 -1.20
Current Ratio
9/30/24 Pending Next EPS Report
6/30/24 1.91
3/31/24 1.73
Quick Ratio
9/30/24 Pending Next EPS Report
6/30/24 1.69
3/31/24 1.49
Operating Margin
9/30/24 Pending Next EPS Report
6/30/24 0.83
3/31/24 -2.60
Net Margin
9/30/24 Pending Next EPS Report
6/30/24 0.83
3/31/24 -2.60
Pre-Tax Margin
9/30/24 Pending Next EPS Report
6/30/24 5.94
3/31/24 -1.01
Book Value
9/30/24 Pending Next EPS Report
6/30/24 17.38
3/31/24 16.90
Inventory Turnover
9/30/24 Pending Next EPS Report
6/30/24 0.97
3/31/24 0.94
Debt-to-Equity
9/30/24 Pending Next EPS Report
6/30/24 0.00
3/31/24 0.00
Debt to Capital
9/30/24 Pending Next EPS Report
6/30/24 0.00
3/31/24 0.00